Canada Mortgage and Housing Corporation

Under the Access to Information Act, I am requesting a copy of the Operating Agreement (and any amendments, schedules, or renewal documents) between Canada Mortgage and Housing Corporation (CMHC) and Eamon Park Housing Co-operative Inc., located at 94 David Lewis Drive, Concord, Ontario. Please also include any related correspondence or program documentation establishing the effective date, duration, and funding terms of this agreement. Please process this request without consulting or notifying Eamon Park Housing Co-operative directly, as the records requested concern administrative agreements between CMHC and the Co-operative, not personal or third-party information.

Please provide all communications between the government relations team at CMHC and anyone with any of these email suffixes: @gov.mb.ca, leg.gov.mb.ca, @manitoba.ca that have these keyword searches in their subject, body or an attachment: Canada Manitoba Housing Benefit, CMHB, homelessness, Canada-Manitoba Housing benefit Dates: July 1, 2024 to date of receipt

Any funding agreements, funds received as well as any reports on housing for the Ta'an Kwach'an Council as well as the location of any housing received after signing their final agreement (Self-Government Agreement) since January 2002.

Please provide any research reports, memos, briefing notes, and presentations (both slide decks and speaking notes, if they exist) that discuss the use of blanket appraisals or other appraisal practices that could value real estate assets above their market price, from November 1, 2024 to the date you begin processing this request.

Provide records broken down as such: raw text of all user-entered prompts input to Outlook Copilot for writing, editing, or summarizing emails, and any exports that contain those prompts (e.g., Outlook/Copilot admin or audit exports limited to Outlook) used by the Communications/Communications Division unit of Canada Mortgage and Housing Corporation from February 1, 2025 to October 8, 2025. Include, where available in the same records: timestamp, Copilot feature invoked (draft/rewrite/edit/summarize), and a non-identifying user attribute (role or group). Exclude French records and duplicate copies. Sort by earliest date to latest date. If no such records exist, include records indicating whether Outlook Copilot prompts are retained/logged for this unit and the date/configuration under which such records became unavailable. Provide documents as searchable PDFs and any tabular data as CSV.

The “Teams usage report” and “Teams user activity report.” I am seeking all available metrics for all employees. I understand these reports come in 30, 60, 90 or 180 periods. I am seeking the 180-day report. 2. Any official Microsoft Teams usage and/or retention policies or guidelines. Please contact me if you require any clarification."

I would like to get a comprehensive spreadsheet of all of the information from the 2824 forms filed for all 965 and 966 pool types since January 2020, including the name of the issuer for each pool, the pool #, pool issue date, pool maturity date, opening principal balance of pool, interest rate of pool, pool administrator and details of each loan in the pool including principal balance of loan, loan interest rate, term of loan in months, interest adjustment date, final payment date, mortgagor’s name, property address, postal code of mortgaged property and mortgage loan originator.

All loan-level data for CMHC-insured construction mortgages currently outstanding under the Apartment Construction Loan Program (ACLP), including but not limited to: Loan origination date Original loan amount Outstanding balance Property type and location (e.g., postal code or census division) Borrower credit score (if available) Loan-to-value ratio at origination Insurance premium paid Mortgage term and amortization Interest rate type (fixed/variable) Issuing financial institution Default status (if applicable) Number of loans Average loan size I am requesting this data in machine-readable format (e.g., CSV, Excel, or database export) if available

Adverse Drug Reactions (ADRs). Report numbers: 001151822, E2B_06755516, E2B_08087356.

Adverse Drug Reactions (ADRs). Report numbers: E2B_05752679, E2B_02695771, E2B_04384481, E2B_03467903, E2B_06236521, E2B_06228427, E2B_02394438, E2B_02999200, E2B_03013515, E2B_03157176.

Adverse Drug Reaction (ADR). Report number: 001134997.

Adverse Drug Reactions (ADRs). Report numbers: 001100488, 001103644, 001117123, 001090170, 001085506, 001089506, 001092361, 001097665, 001080798.

Adverse Drug Reactions (ADRs). Report numbers: 001148976, 001151091.

Adverse Drug Reaction (ADR). Report number: 001148330.

Adverse Drug Reaction (ADR). Report number: E2B_08032533.

Adverse Drug Reaction (ADR). Report number: 001129176.

Adverse Drug Reactions (ADRs) for FUROSEMIDE. Report numbers: 000950278, E2B_04166817, 000955013, 000961451, 000962356, E2B_04502921, 000952777, E2B_04303974, 000958693, 000966676, 000966336, 000965870, 000966529, 000966529, 000953889, 000963164, 000959463, 000966420, 000966836, 000966836.

Adverse Drug Reaction (ADR) for MESALAZINE. Report number: E2B_06239098. ADR for VYVANSE. Report number: 001031402. ADRs for IMMUNOGLOBULIN (HUMAN). Report numbers: E2B_06233987, E2B_06204721, E2B_06223784. ADR for ICATIBANT (ICATIBANT ACETATE). Report number: E2B_06218670. ADRs for ANTIHEMOPHILIC FACTOR (HUMAN). Report numbers: E2B_06250890, E2B_06262722. ADR for LANSOPRAZOLE. Report number: 001033897.

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 25-103816-354, Food Safety Assessment of Pigs Gene Edited to Be Resistant to a Virus.

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-113357-409, Meeting with AstraZeneca Canada.

Adverse Drug Reactions (ADRs). Report numbers: E2B_06836385, E2B_05660423, E2B_06797022.

Adverse Drug Reactions (ADRs). Report numbers: 001142430, E2B_07951454, E2B_07861592, E2B_07940257, E2B_07951181, E2B_07907603, E2B_07901168, E2B_07961949.

Adverse Drug Reactions (ADRs) for Leuprolide. Report numbers: 1145217, 1146194. ADR for Zeulide. Report number: 1147594. ADRs for Leuprorelin. Report numbers: E2B_07959616, E2B_07969177, E2B_07984376, E2B_08001732, E2B_08004849, E2B_08007525, E2B_08008825.

Adverse Drug Reaction (ADR). Report number: E2B_07985198.

Aggregate statistics from Human Resources (HR) systems on finalized disciplinary measures imposed on Health Canada employees from 2018 - 2025, by branch, year, nature of misconduct, and type of disciplinary measure. Final versions of the Health Canada Code of Conduct and Disciplinary Framework(s) in effect between 2010 and 2025.

Adverse Drug Reactions (ADRs). Report numbers: E2B_03824918, E2B_05426524, E2B_06109018, E2B_06206904, 001034434, 001031775, E2B_05649794, E2B_06238976, E2B_05926116, E2B_06191407.

Search under the company names listed below and send us a copy of any documents related to Expédibox inc.

The names and addresses of all employees who were inside the Clinic located at 4920 Sherbrooke Street West, Montréal, H1Z 4H9 at the time of the compliance audit conducted by Health Canada on September 18, 2025.

For Fiscal Year 2024-2025, finalized records that show what happened to the Drugs for Rare Diseases (DRD) monies in cases where any province or territory did not spend its full allocation.

Adverse Drug Reactions (ADRs). Report numbers: E2B_08078972, E2B_08037188, 001151520, E2B_00146713, E2B_08041934, E2B_08056676.

Adverse Drug Reactions (ADRs). Report numbers: E2B_04399875, E2B_04593072, E2B_04507225, E2B_04599363, 000966627, E2B_04541270, E2B_04553510, E2B_04514874, E2B_04540526, E2B_04568705, E2B_04588475, E2B_01565006, E2B_04533996, E2B_04613296, E2B_04582435, E2B_04441940, E2B_04594436, E2B_04584019, E2B_02032501, E2B_04510114.

Briefing notes, issue analyses, or summary correspondence prepared for or by Director-level employees and above at Health Canada regarding concerns about problematic or addictive use of the gaming platform Roblox, from January 1, 2019, to October 23, 2025.

Adverse Drug Reactions (ADRs). Report numbers: 000935006, E2B_03663954, 000933378, E2B_02358439, E2B_02585464, E2B_03726837, 000935470, 000942342, E2B_02585464, E2B_03467903, E2B_03787522, E2B_03823712, 000945379, E2B_00026099, E2B_03125928.

Adverse Drug Reactions (ADRs) for LEFLUNOMIDE. Report numbers: 965008, E2B_04130660, E2B_04143579, E2B_04186572, 953771, E2B_04134053, E2B_04212348.

All records/information pertaining to the ALMA TED device.

The Abbreviated New Drug Submission (ANDS) cover letter submitted by Taro for the June 2025 Semaglutide ANDS.

A copy of the Health Canada’s presentation at the meeting held on June 25, 2025 between the Canadian Generic Pharmaceutical Association (CGPA) and the Pharmaceutical Drugs Directorate.

Adverse Drug Reactions (ADRs) for LEFLUNOMIDE. Report numbers: 931634, E2B_02411125, E2B_03710790, E2B_03523167, E2B_03522972, E2B_03591954, E2B_03553706, E2B_04381129, E2B_03567453, E2B_03547956, E2B_03701315, E2B_03706111.

The most recent financial statement, summary, or report that outlines all costs Health Canada has incurred to date, both internal and external, for its legal defence against lawsuits filed by Parkland Corporation and Couche-Tarde regarding the Ministerial Order on nicotine pouches issued in August 2024 (Supplementary Rules Respecting Nicotine Replacement Therapies Order: SOR/2024-169).

Adverse Drug Reaction (ADR) for DICLOFENAC SODIUM. Report number: E2B_04515703.

With respect to the data disclosed related to total number of non- compliant ratings issued to Licenced Producers (LPs) where non-compliance with Part 11 of the Cannabis Regulations was a contributing factor to receiving the non-compliant rating, provide the following: 35 non- compliant ratings were indicated; provide each inspection report documenting these non-compliant ratings or provide a compilation of the observations issued under each of the 35 non-compliant ratings. This data covers the period of January `1 to December 31, 2024.

Adverse Drug Reactions (ADRs) for ZOPICLONE. Report numbers: E2B_04307076, E2B_04312675, E2B_04540084, E2B_04486300, 000969511, E2B_04556853, E2B_04310291, 000970042, E2B_04306428, E2B_04559078, E2B_04559269, E2B_04610347, E2B_04460357, E2B_04168173, E2B_04563990.

All records that reference, discuss, or relate to the letter issued by the Call2Halt under the banner of "Call to Halt 19" or "Call to Halt-19" dated March 31, 2025 entitled Canadian Open Letter of Concern Regarding COVID-19 modRNA Vaccines. All records that reference, discuss, or relate to emails from the Call to Halt-19 Organizing Committee sent May to July 2025 to alert government officials/representives about this Open Letter with the subject line: Canadian Open Letter, a Call to Halt the COVID-19 mRNA vaccines. Time frame: from May 26, 2025 to October 22, 2025.

Adverse Drug Reactions (ADRs) for MESALAZINE. Report numbers: E2B_06455244, E2B_06408576. ADRs for MESALAMINE. Report numbers: E2B_06416176, E2B_06424494, E2B_06424894. ADRs for VYVANSE. Report numbers: 001044544, 001044760, 001045806, E2B_06428692.

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 24-110989-118, Meeting with United States Ambassador to Canada.

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 24-075334-568, University of Ottawa Leadership in the Age of Climate Change Program.

Any comments received as part of the consultation on the updated policy on foods derived from animals cloned by somatic cell nuclear transfer and their progeny. Failing that, a list of all the people or organizations that have submitted a comment as part of this consultation.

Documents related to the following medical devices: HILO (license no. 107981) and HILOSPOT (license no 112665). All records related to approval of the aforementioned medical devices. Documents submitted under section 32(1) and section 32(2) of the Medical Devices Regulations. All related correspondence between Health Canada and the manufacturer.The results or detailed descriptions of any investigational testing submitted in respect of the devices.

Documents that would illustrate the public/third parties not in any level of government, who have received payment, reward, or compensation from Health Canada, between 2005-02-14 and 2025-10-01, for the creation of videos intended for the publishing on YouTube whether or not such publishing actually occurred. Documents only need to show amount paid - to whom and what video the payment was received for.

For the Abbreviated New Drug Submission (ANDS) filed by Sandoz Canada Incorporated for ivacaftor, provide copies of any Notice of Deficiency (NOD); Notice of Non-Compliance (NON); NOD-Withdrawal (NOD-W), a NON-Withdrawal (NON-W) and any responses from the sponsor to same.